{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    21,
    22,
    23,
    24,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Arm A",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Atezolizumab 1200 mg IV infusion every 3 weeks (Q3W) and bevacizumab 15 mg/kg IV Q3W"
      },
      {
        "id": "arm_2",
        "name": "Arm B",
        "type": {
          "code": "Active Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Active Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Sorafenib 400 mg by mouth, twice a day (BID), continuously"
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Global Enrollment Phase",
        "instanceType": "StudyCohort",
        "characteristic": "Approximately 480 patients enrolled globally"
      },
      {
        "id": "cohort_2",
        "name": "China Subpopulation",
        "instanceType": "StudyCohort",
        "characteristic": "Approximately 135 patients from mainland China, including those from the global phase and an extended China enrollment phase"
      }
    ],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Arm A - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm A during Screening"
      },
      {
        "id": "elem_2",
        "name": "Arm A - Treatment Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm A during Treatment Phase"
      },
      {
        "id": "elem_3",
        "name": "Arm A - Survival Follow-Up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm A during Survival Follow-Up"
      },
      {
        "id": "elem_4",
        "name": "Arm B - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm B during Screening"
      },
      {
        "id": "elem_5",
        "name": "Arm B - Treatment Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm B during Treatment Phase"
      },
      {
        "id": "elem_6",
        "name": "Arm B - Survival Follow-Up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm B during Survival Follow-Up"
      }
    ],
    "summary": {
      "armCount": 2,
      "cellCount": 6,
      "cohortCount": 2,
      "elementCount": 6
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "2:1"
      },
      "stratificationFactors": [
        "Geographic region (Asia excluding Japan vs. rest of world)",
        "Macrovascular invasion and/or extrahepatic spread (presence vs. absence)",
        "Baseline alpha-fetoprotein (<400 vs. >=400 ng/mL)",
        "Eastern Cooperative Oncology Group Performance Status (0 vs. 1)"
      ],
      "controlType": {
        "code": "Active Control",
        "codeSystem": "USDM",
        "decode": "Active Control"
      },
      "armIds": [
        "arm_1",
        "arm_2"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Oncology",
        "Hepatology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "2:1",
        "stratificationFactors": [
          "Geographic region (Asia excluding Japan vs. rest of world)",
          "Macrovascular invasion and/or extrahepatic spread (presence vs. absence)",
          "Baseline alpha-fetoprotein (<400 vs. >=400 ng/mL)",
          "Eastern Cooperative Oncology Group Performance Status (0 vs. 1)"
        ]
      },
      "controlType": "Active Control",
      "therapeuticAreas": [
        "Oncology",
        "Hepatology"
      ]
    },
    "arms": [
      {
        "name": "Arm A",
        "type": "Experimental Arm",
        "description": "Atezolizumab 1200 mg IV infusion every 3 weeks (Q3W) and bevacizumab 15 mg/kg IV Q3W",
        "isTitration": false,
        "doseEpochs": null
      },
      {
        "name": "Arm B",
        "type": "Active Comparator",
        "description": "Sorafenib 400 mg by mouth, twice a day (BID), continuously",
        "isTitration": false,
        "doseEpochs": null
      }
    ],
    "cohorts": [
      {
        "name": "Global Enrollment Phase",
        "characteristic": "Approximately 480 patients enrolled globally"
      },
      {
        "name": "China Subpopulation",
        "characteristic": "Approximately 135 patients from mainland China, including those from the global phase and an extended China enrollment phase"
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Assessment of eligibility criteria and baseline tumor scans"
      },
      {
        "name": "Treatment Phase",
        "description": "Administration of study treatment in 3-week cycles until unacceptable toxicity or loss of clinical benefit"
      },
      {
        "name": "Survival Follow-Up",
        "description": "Followed for survival and subsequent anti-cancer therapies until death or study termination"
      }
    ]
  }
}